5 Key Takeaways

• 1

  Harold Keer describes industry as a way to scale individual discoveries into medicines for patients, calling it “the ultimate translational medicine.”.

• 2

  Cancer treatment has expanded from cytotoxic chemotherapy to targeted therapies, monoclonal antibodies, immunotherapies, bispecific antibodies, and antibody-drug conjugates.

• 3

  RAS, once considered an “undruggable” target, is now a competitive area of drug development.

• 4

  Keer discusses why promising cancer programs fail and the promise and possible “irrational exuberance” surrounding emerging treatment modalities.

• 5

  Keer says his unfinished business is helping Taiho’s newly acquired antibody-drug conjugate technology reach the clinic.